Recently published ANSWER Program data on patients with Noonan syndrome with a mean referral age of 9 years showed that baseline age was negatively correlated with ΔHSDS after 1 or 2 years of GH treatment, indicating that older baseline ATS resulted in lower ΔHSDS [27–29]. This evidence concerns the gene GH1 and Noonan syndrome.